Adalimumab in Adult Japanese Subjects With Psoriasis
Information source: Abbott
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Psoriasis
Intervention: adalimumab (Biological); adalimumab (Biological)
Phase: Phase 2/Phase 3
Status: Active, not recruiting
Sponsored by: Abbott Official(s) and/or principal investigator(s):
Noritaka Inomata, Ph.D., Study Director, Affiliation: Abbott
Summary
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with
psoriasis
Clinical Details
Official title: A Multicenter Open-Label Continuation Study of the Long-Term Safety and Efficacy of Adalimumab (D2E7) in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study design: Treatment, Non-Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study
Primary outcome: PASI 50 Response
Secondary outcome: PASI75/90Incidence of AEs
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subjects who completed study M04-688
Exclusion Criteria:
- Subject is considered by the investigator, for any reason, to be an unsuitable
candidate for the study
Locations and Contacts
Hokkaido, Japan
Iwate, Japan
Miyagi, Japan
Fukushima, Japan
Tochigi, Japan
Chiba, Japan
Tokyo, Japan
Kanagawa, Japan
Ishikawa, Japan
Gifu, Japan
Shizuoka, Japan
Aichi, Japan
Mie, Japan
Kyoto, Japan
Osaka, Japan
Hyogo, Japan
Okayama, Japan
Hiroshima, Japan
Yamaguchi, Japan
Tokushima, Japan
Kochi, Japan
Fukuoka, Japan
Nagasaki, Japan
Kagoshima, Japan
Additional Information
Starting date: April 2006
Last updated: March 27, 2008
|
